- Home
- SLGL vs GALT Comparison
SLGL vs GALT Comparison
Compare SLGL & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGL | GALT |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.1M | 199.2M |
| IPO Year | 2016 | 2008 |
Fundamental Metrics
Financial Performance| Metric | SLGL | GALT |
|---|---|---|
| Price | $77.67 | $2.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $110.00 | $8.50 |
| AVG Volume (30 Days) | 50.6K | ★ 346.5K |
| Earning Date | 05-22-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $223.84 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $1.22 |
| 52 Week High | $97.97 | $7.13 |
Technical Indicators
Market Signals| Indicator | SLGL | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 52.11 | 45.18 |
| Support Level | $70.31 | $2.18 |
| Resistance Level | $84.75 | $2.60 |
| Average True Range (ATR) | 5.57 | 0.18 |
| MACD | 0.21 | 0.02 |
| Stochastic Oscillator | 55.88 | 46.25 |
Price Performance
Historical ComparisonAbout SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.